Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 15;24(8):7329.
doi: 10.3390/ijms24087329.

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review

Ching-Ya Wang  1   2 , Chuang-Wei Wang  1   3   4   5 , Chun-Bing Chen  1   2   3   4   5   6   7   8 , Wei-Ti Chen  1   2   5 , Ya-Ching Chang  1   2 , Rosaline Chung-Yee Hui  2   9 , Wen-Hung Chung  1   2   3   4   5   6   7   8   9   10   11   12
Affiliations
Review

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review

Ching-Ya Wang et al. Int J Mol Sci. .

Abstract

The efficacy and the safety of psoriasis medications have been proved in trials, but unideal responses and side effects are noted in clinical practice. Genetic predisposition is known to contribute to the pathogenesis of psoriasis. Hence, pharmacogenomics gives the hint of predictive treatment response individually. This review highlights the current pharmacogenetic and pharmacogenomic studies of medical therapy in psoriasis. HLA-Cw*06 status remains the most promising predictive treatment response in certain drugs. Numerous genetic variants (such as ABC transporter, DNMT3b, MTHFR, ANKLE1, IL-12B, IL-23R, MALT1, CDKAL1, IL17RA, IL1B, LY96, TLR2, etc.) are also found to be associated with treatment response for methotrexate, cyclosporin, acitretin, anti-TNF, anti-IL-12/23, anti-IL-17, anti-PDE4 agents, and topical therapy. Due to the high throughput sequencing technologies and the dramatic increase in sequencing cost, pharmacogenomic tests prior to treatment by whole exome sequencing or whole genome sequencing may be applied in clinical in the future. Further investigations are necessary to manifest potential genetic markers for psoriasis treatments.

Keywords: adverse effect; drug; pharmacogenetics; pharmacogenomics; polymorphisms; psoriasis; treatment response; whole genome sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immunopathogenesis of psoriasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Capon F. The Genetic Basis of Psoriasis. Int. J. Mol. Sci. 2017;18:2526. doi: 10.3390/ijms18122526. - DOI - PMC - PubMed
    1. Rahman P., Schentag C.T., Beaton M., Gladman D.D. Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis. Ann. Rheum. Dis. 2000;18:7–12. - PubMed
    1. Yan D., Gudjonsson J.E., Le S., Maverakis E., Plazyo O., Ritchlin C., Scher J.U., Singh R., Ward N.L., Bell S., et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. J. Investig. Dermatol. 2021;141:2112–2122.e3. doi: 10.1016/j.jid.2021.02.764. - DOI - PMC - PubMed
    1. Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019;20:1475. doi: 10.3390/ijms20061475. - DOI - PMC - PubMed
    1. Sweeney C.M., Tobin A.-M., Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch. Dermatol. Res. 2011;303:691–705. doi: 10.1007/s00403-011-1169-1. - DOI - PubMed